The Science
Evidence-based care, proven results
Every treatment we offer at Anywhere Clinic is grounded in peer-reviewed research and FDA-cleared protocols. Below is a clinician-level look at the science behind ketamine therapy, TMS, Spravato®, and our integrative psychiatry model, including the trials, mechanisms, and response rates that inform how we treat depression, anxiety, PTSD, and OCD.
Ketamine Therapy
50–70% response within 72 hoursRapid-acting glutamate modulation for treatment-resistant depression
Ketamine antagonizes NMDA receptors in the prefrontal cortex, triggering a downstream cascade that promotes synaptogenesis, the growth of new neural connections via BDNF (brain-derived neurotrophic factor) signaling. Unlike SSRIs, which take 4–8 weeks to alter serotonin pathways, ketamine often produces measurable mood improvement within hours.
Clinical evidence
A 2019 meta-analysis in the American Journal of Psychiatry pooled 28 randomized trials and reported response rates of 50–70% in treatment-resistant depression within 24–72 hours of dosing. Ongoing maintenance protocols (4–6 sessions over 2–3 weeks) have demonstrated sustained remission in approximately 40% of patients at 6-month follow-up.
TMS (Transcranial Magnetic Stimulation)
50–60% response, 30–40% remissionNon-invasive cortical stimulation, FDA-cleared since 2008
TMS delivers focused magnetic pulses (1.5–2 Tesla) to the left dorsolateral prefrontal cortex (DLPFC), an area of the brain that is hypoactive in major depression. Repeated sessions induce long-term potentiation (LTP), strengthening synaptic connections in mood-regulating networks. Patients sit awake in a chair; there's no anesthesia, no sedation, and no systemic side effects.
Clinical evidence
The landmark OPT-TMS trial (NIMH, 2010) demonstrated 50–60% response and 30–40% remission rates after 4–6 weeks of daily sessions in patients who had failed at least one antidepressant. Subsequent FDA clearances have extended TMS use to OCD (2018) and adolescent depression (2024). Newer accelerated SAINT protocols compress treatment to 5 days with comparable or improved outcomes.
Spravato® (Esketamine)
FDA-approved 2019 (TRD), 2020 (suicidality)FDA-approved nasal esketamine for treatment-resistant depression
Spravato® is the S-enantiomer of ketamine, formulated as a nasal spray and administered under direct medical observation in a certified REMS clinic. It binds NMDA receptors with greater affinity than racemic ketamine, producing similar rapid antidepressant effects with a defined dose and observed safety window (2-hour monitoring per session).
Clinical evidence
FDA approval (2019) was based on the TRANSFORM-2 phase 3 trial, which showed Spravato® plus an oral antidepressant produced a statistically significant reduction in MADRS depression scores within 24 hours versus placebo plus antidepressant. The SUSTAIN-1 maintenance trial demonstrated a 51% lower risk of relapse over 16 weeks. In 2020, the FDA expanded approval to include depressive symptoms with acute suicidal ideation.
Integrative Psychiatry
+15–20% remission vs. meds aloneWhole-person care: pharmacotherapy + psychotherapy + lifestyle
Our model layers evidence-based pharmacotherapy (SSRIs, SNRIs, atypical antipsychotics, stimulants, mood stabilizers) with structured psychotherapy modalities, Cognitive Behavioral Therapy (CBT), Dialectical Behavior Therapy (DBT), Eye Movement Desensitization and Reprocessing (EMDR), and Acceptance and Commitment Therapy (ACT), and lifestyle medicine including sleep hygiene, exercise prescription, and nutritional psychiatry.
Clinical evidence
The STAR*D trial (NIMH) showed that combining medication with structured psychotherapy increases remission rates by 15–20% over medication alone. Research from the World Federation of Societies of Biological Psychiatry (WFSBP) supports stepped-care models that escalate from first-line treatments to interventional options like TMS, ketamine, or ECT when standard care fails.
Ketamine, in depth
How ketamine acts on the brain
Ketamine works on the NMDA-glutamate system rather than the serotonergic pathway targeted by SSRIs. Research describes downstream effects on synaptic plasticity. Ketamine is prescribed off-label and is not FDA-approved for psychiatric conditions; suitability is determined individually by a licensed clinician. Learn more about our at-home ketamine program or read the full step-by-step program.
NMDA receptor antagonism
Ketamine blocks NMDA glutamate receptors on inhibitory interneurons, producing a downstream surge of glutamate signaling at AMPA receptors in the prefrontal cortex.
BDNF & synaptogenesis
That glutamate surge triggers release of brain-derived neurotrophic factor (BDNF), which fertilizes the growth of new dendritic spines and synapses within hours of dosing.
Restored neuroplasticity
Chronic stress, depression, and trauma atrophy prefrontal circuits. Ketamine reopens a window of neuroplasticity, the ideal moment to pair dosing with integration therapy.
Established safety profile
Ketamine has been used clinically for over 50 years. It has a wide therapeutic index, cardiovascular stability, minimal respiratory depression, and a low dependence risk under supervised dosing.
Why patients choose at-home ketamine
- Mechanism of action differs from SSRIs, NMDA receptor modulation rather than serotonergic reuptake inhibition
- Studied in peer-reviewed trials for several psychiatric indications; ketamine is prescribed off-label and is not FDA-approved for psychiatric conditions
- Sublingual at-home protocol avoids the cost and burden of in-clinic IV infusions for appropriate patients
- Pairs with integration therapy as part of a structured psychiatric care plan
- Insurance-eligible psychiatry visits; compounded medication, when prescribed, is paid through the pharmacy
How we practice
Principles behind every treatment plan
"Evidence-based" isn't a marketing phrase for us, it's the operating system for our clinic. Here's how we translate research into the care you actually receive.
Peer-reviewed evidence
Every protocol we offer is grounded in randomized controlled trials, meta-analyses, and clinical guidelines from the APA, WFSBP, and FDA labeling.
Measurement-based care
We use validated rating scales (PHQ-9, GAD-7, MADRS, YBOCS) at baseline and follow-ups to track symptom change objectively, not just by impression.
Continuous education
Our providers attend conferences (APA Annual Meeting, Wonderland, MAPS) and complete CME on emerging treatments, including psychedelic medicine, neuromodulation, and digital therapeutics.
Personalized stepped care
Treatment escalates based on response. Most patients start with first-line therapy and medication; we add interventional options like TMS, ketamine, or Spravato® only when clinically warranted.
Common questions about the science
Plain-language answers to the technical questions patients ask most often.